dihexa human clinical trials or studies trial status Dihexa shows neurotrophic activity exceeding BDNF in preclinical DIHEXA | Peptide Synthetic dihexa human clinical trials data

A new bloodbrain barrier model using primary rat brain endothelial cells, pericytes and astrocytes

Peptide Vials (DSIP, 5 mg each): 8 weeks at ~200 mcg/day avg 23 vials 12 weeks at ~200 mcg/day avg 34 vials 12 weeks at ~300 mcg/day avg 56 vials Insulin Syringes (U-100): Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution

Blood-brain-barrier-penetrant AngIV analog Studied as a metabolically stabilized, orally active angiotensin-IV derivative designed to reach the brain in animal pharmacokinetic work

Mild rashes usually go away without stopping the medicine, but if you notice blisters, peeling skin, or swelling, it could be a sign of a serious allergic reaction